Data demonstrate long-term, low back pain relief with Boston Scientific Precision Spectra system


New retrospective data evaluating the Boston Scientific Precision Spectra spinal cord stimulator system demonstrate that the device provided sustained and significant relief of low back pain 12 months after implantation. Results from the PRO study are being presented at the 18th North American Neuromodulation Society (NANS; December 11–14) meeting in Las Vegas, USA.

The outcomes review of 213 patients at 13 centres focuses on patients with chronic pain and chronic low back pain who are receiving treatment with the Precision Spectra system. The system’s Illumina 3D software, an anatomy-driven computer model designed for simple point-and-click pain targeting, helps to address a key challenge in long term back pain relief; stimulating the neural target without stimulating undesired areas.

At 12 months post-implantation, sustained and significant reduction in overall pain measured on the 0-10 numeric rating scale (NRS) was reported, from an average baseline score of 7.17, to an average score of 2.96 at 12 months post-implantation (n= 178). In patients with only low back pain (n= 73), a sustained and significant reduction of low back pain was reported, from an average NRS baseline score of 7.21 to an average of 3.17 at 12 months post-implantation. In patients with severe low back pain (n= 41, baseline score of 8 or greater measured on the 0-10 NRS scale), sustained and significant reduction in pain was reported, from an average score of 8.60 at baseline to 2.87 at 12 months post-implantation. The cohort will be followed through the 24-month interval.

“Treating low back pain has been challenging because so many therapies have had mixed results,” explains Salim Hayek, chief, Division of Pain Medicine at University Hospitals of Cleveland and lead study investigator. “These results demonstrate that the Precision Spectra system can provide effective, long-term relief for patients suffering from this difficult to treat condition.”

“This long-term, ’real-world’ study reflects our continuing commitment to advancing the science of pain relief to help achieve better outcomes for patients with chronic pain,” says Maulik Nanavaty, president, neuromodulation, Boston Scientific.